ProPhase Labs Net Profit Margin 2010-2025 | PRPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ProPhase Labs net profit margin from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ProPhase Labs net profit margin from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$76.5B
Zoetis (ZTS)	$69.3B
Takeda Pharmaceutical (TAK)	$47.9B
Daiichi Sankyo, - (DSNKY)	$42.7B
BeOne Medicines - (ONC)	$27.6B
Sandoz Group AG (SDZNY)	$24.9B
Summit Therapeutics (SMMT)	$18.9B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.4B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.8B
Corcept Therapeutics (CORT)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.1B
Ionis Pharmaceuticals (IONS)	$6.8B
Grifols, S.A (GRFS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.3B
Soleno Therapeutics (SLNO)	$4.2B
Crinetics Pharmaceuticals (CRNX)	$3.1B
Hypermarcas (HYPMY)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B